Department of Radiation Oncology, Institut de Recherche Experimentale et Clinique, Université catholique de Louvain, St-Luc University Hospital, Brussels, Belgium.
EORTC Headquarters, Brussels, Belgium.
Eur J Cancer. 2016 Sep;65:109-12. doi: 10.1016/j.ejca.2016.06.024. Epub 2016 Aug 2.
The long-term results of the EORTC 24954 trial comparing sequential versus alternating chemotherapy and radiotherapy (RT) for patients with locally advanced laryngeal and hypopharyngeal cancer are reported. From 1996 to 2004, 450 patients were randomly assigned (1-1) to a sequential arm (SA = induction cisplatin-5fluorouracil followed by a 70Gy-RT for the responders or a total laryngectomy and post-operative RT for the non-responders) and an alternating arm (AA = cisplatin-5fluorouracil alternated with three 2-week courses of 20 Gy-RT for a total dose of 60 Gy). Median follow-up was 10.2 years. Ten-year survival with functional larynx (primary end-point) and overall survival were similar in both arms (18.7% and 33.6% in SA versus 18.3% and 31.6% in AA). Late toxicity was also similar; however, a trend for higher larynx preservation and better laryngeal function was observed in AA.
EORTC 24954 试验比较了局部晚期喉和下咽癌患者序贯与交替化疗和放疗(RT)的长期结果。该试验于 1996 年至 2004 年入组了 450 例患者,以 1:1 的比例随机分配到序贯组(SA=诱导顺铂-5-氟尿嘧啶,然后对有反应者给予 70Gy-RT,对无反应者给予全喉切除术和术后 RT)和交替组(AA=顺铂-5-氟尿嘧啶交替给予三个 2 周 20Gy-RT 疗程,总剂量为 60Gy)。中位随访时间为 10.2 年。两组的功能保留喉(主要终点)和总生存率相似(SA 组为 18.7%和 33.6%,AA 组为 18.3%和 31.6%)。晚期毒性也相似;然而,在 AA 组中观察到更高的喉保存率和更好的喉功能趋势。